AVA-101 (Avalon/Arbele)

N/A

Report date: 2025/01/26 18:07:18

Base Information

Drug NameAVA-101 (Avalon/Arbele)
Drug Alias Namedual anti-CD19/anti-CD22 CAR T-cell therapy (Avalon/Arbele)AVA-101 (Avalon/Arbele)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvalon Globocare Corp
China Registration ClassN/A

Develop Information

Active CompaniesAvalon Globocare CorpArbele Corp
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A